11 clinical trials found.
-
A randomized phase II trial of adjuvant trastuzumab emtansine (T-DM1) followed by subcutaneous trastuzumab versus paclitaxel in combination with subcutaneous trastuzumab for Stage I HER2-positive breast cancer (ATEMPT 2.0)
In stage 1 (early) HER2+ breast cancer, lesser chemotherapy is needed to achieve excellent long-term survival. The current standard therapy is TH (paclitaxel plus trastuzumab ...Phase
TRIAL ROLE: Principal Investigator
-
A Phase 2 Randomized Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Nab-Paclitaxel or Paclitaxel versus Nab-Paclitaxel or Paclitaxel in Previously Untreated Patients with Metastatic Triple-Negative Breast Cancer
Magrolimab is a novel immune checkpoint inhibitor (targeting macrophages in the tumor to support killing of tumor). The purpose of the study is to determine ...Phase
TRIAL ROLE: Principal Investigator
-
A Phase 1b First-in-human Dose Escalation and Expansion Multicenter Study of XMT-1660 in Participants with Solid Tumors
If you are diagnosed with stage 4 tumor of any solid origin, for example; breast, endometrial, ovarian, fallopian tube, cervix, vaginal or primary peritoneal cancer ...
Phase
TRIAL ROLE: Principal Investigator
-
TAILOR RT: A RANDOMIZED TRIAL OF REGIONAL RADIOTHERAPY IN BIOMARKER LOW RISK NODE POSITIVE BREAST CANCER
The purpose of this study is to determine whether there is any benefit of regional radiotherapy and to compare good and bad effects of not ...Phase
TRIAL ROLE: Sub Investigator
-
Site for EA1181 (CompassHER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response
The purpose of the study is to determine the safety and tolerability of pre-operative therapy with 12 weeks of taxane, trastuzumab (or FDA approved biosimilar ...Phase
TRIAL ROLE: Sub Investigator
-
A randomized Phase I/II trial of fulvestrant and abemaciclib in combination with copanlisib (FAC) versus fulvestrant and abemaciclib alone (FA) for endocrine-resistant hormone receptor positive HER2 negative metastatic breast cancer (FAC vs FA)
The purpose of the study is to determine the effects (good and bad) of adding copanlisib to the usual therapy of fulvestrant and abemaciclib in ...Phase
TRIAL ROLE: Sub Investigator
-
A Phase Ib/II Multicenter Open-label Modular Dose-Finding and Dose Expansion Study to Explore the Safety Tolerability and Anti-tumor Activity of Trastuzumab Deruxtecan (DS-8201a T-DXd) in Combination with other Anti-cancer Agents in Patients with Metastatic HER2-positive Breast Cancer (DESTINY-Breast07)
The purpose of the study is to determine if study drug Trastuzumab Deruxtecan (T-DXd) can be given safely in combination with other cancer treatments to ...Phase
TRIAL ROLE: Sub Investigator
-
The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD) A Double-Blinded Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
The purpose of the study is to determine if the invasive disease-free survival (iDFS) with T-DM1 and tucatinib is superior to the iDFS in the ...Phase
TRIAL ROLE: Sub Investigator
-
A Phase 2 Clinical Study of TJ004309 in Combination With Atezolizumab (TECENTRIQ ) in Patients With Advanced or Metastatic Ovarian Cancers and Selected Advanced Solid Tumors
The purpose of the study to determine the efficacy of TJ004309 (anti- CD-73 ab )in combination with atezolizumab (PDL-1 inhibitor) immunotherapy in patients with advanced ...Phase
TRIAL ROLE: Sub Investigator
-
Phase II Trial of Radium-223 Dichloride in Combination with Paclitaxel in Patients with Bone Metastatic Breast Cancer
The purpose of the study is to determine the safety and efficacy of the combination of Radium-223 dichloride and paclitaxel. We want to know if ...Phase
TRIAL ROLE: Sub Investigator
